The document summarizes several studies on ovarian cancer presented at the 2013 ASCO Annual Meeting. It discusses phase I/II trials of olaparib and cediranib combination therapy, paclitaxel/carboplatin with or without sorafenib as first-line treatment, bevacizumab and temsirolimus for recurrent ovarian cancer, and the effect of metformin on disease-free survival in diabetic ovarian cancer patients. It also mentions feasibility and safety studies of bevacizumab after neoadjuvant chemotherapy and metronomic chemotherapy for recurrent ovarian cancer.

1. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting
ASCO CIM 2013
Cáncer de ovario
Dra . Sofía Alsina Sarmiento
Servicio: Oncología Médica INOR
Presentaciones orales
Resúmenes
Notas ASCO

2. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

3. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

4. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

5. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

6. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

7. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

8. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

9. [TITLE]
Presented By Eric Pujade-Lauraine, M.D., Ph.D. at 2013 ASCO Annual Meeting

10. [TITLE]
Presented By Andreas Du Bois, MD at 2013 ASCO Annual Meeting

11. [TITLE]
Presented By Andreas Du Bois, MD at 2013 ASCO Annual Meeting

12. [TITLE]
Presented By Andreas Du Bois, MD at 2013 ASCO Annual Meeting

13. [TITLE]
Presented By Andreas Du Bois, MD at 2013 ASCO Annual Meeting

14. [TITLE]
Presented By Sean Kehoe, MD at 2013 ASCO Annual Meeting

15. [TITLE]
Presented By Sean Kehoe, MD at 2013 ASCO Annual Meeting

16. [TITLE]
Presented By Sean Kehoe, MD at 2013 ASCO Annual Meeting

17. [TITLE]
Presented By Sean Kehoe, MD at 2013 ASCO Annual Meeting

18. [TITLE]
Presented By Sean Kehoe, MD at 2013 ASCO Annual Meeting

19. [TITLE]
Presented By Sean Kehoe, MD at 2013 ASCO Annual Meeting

20. [TITLE]
Presented By Sean Kehoe, MD at 2013 ASCO Annual Meeting

21. [TITLE]
Presented By Andres Cervantes-Ruiperez, MD at 2013 ASCO Annual Meeting

22. [TITLE]
Presented By Andres Cervantes-Ruiperez, MD at 2013 ASCO Annual Meeting

23. [TITLE]
Presented By Andres Cervantes-Ruiperez, MD at 2013 ASCO Annual Meeting

24. [TITLE]
Presented By Andres Cervantes-Ruiperez, MD at 2013 ASCO Annual Meeting

25. [TITLE]
Presented By Andres Cervantes-Ruiperez, MD at 2013 ASCO Annual Meeting

26. [TITLE]
Presented By Sandro Pignata, MD, PhD at 2013 ASCO Annual Meeting

27. [TITLE]
Presented By Sandro Pignata, MD, PhD at 2013 ASCO Annual Meeting

28. [TITLE]
Presented By Sandro Pignata, MD, PhD at 2013 ASCO Annual Meeting

29. [TITLE]
Presented By Sandro Pignata, MD, PhD at 2013 ASCO Annual Meeting

30. [TITLE]
Presented By Sandro Pignata, MD, PhD at 2013 ASCO Annual Meeting

31. ASCO 2013.
Ovario.
Resúmenes a
considerar

32. 5505. Olaparib de mantenimiento
en pacientes con
carcinoma de ovario seroso
platino sensibles y mutación del BRCA.
(UK)
166 pacientes.
A confirmar en EC fase III.

33. • 5513. Paclitaxel/Carboplatino con o sin
Sorafenib como primera línea
en cáncer de ovario III/IV. Estudio fase II.
Sarah Cannon Research Institute. EUA. 85
pacientes.
El Sorafenib no mejoró la eficacia. Aumentó
toxicidad.

34. • 5517.Bevacizumab y Temsirolimus en cáncer
de ovario recurrente.
EUA.Fase II multicentros.
Basado en que la combinación de
antiangionénicos e inhibidores de mTOR
teóricamente deben mejorar su actividad.
58 pacientes. El estudio sugiere mejoría de la
actividad potencial con la combinación, pero
evaluar por toxicidad

35. • 5522 Efecto del Metformin en la supervivencia
libre de recurrencia y supervivencia global en
pacientes diabéticas afectas de cáncer de
ovario. Italia.
De 888 pacientes con cáncer de ovario 42
diabéticas (estudio MIMOSA, abagovomab vs
placebo: igual).
Impacto favorable.

36. • 5541. Factibilidad y seguridad del
Bevacizumab después de quimioterapia
neoadyuvante para cáncer de ovario. Israel.
150 pacientes.
Qtp neoayuvante+Beva+qtp: factible y
tolerable.

37. • 5545. Beva en borderline seroso recurrente o
seroso de bajo grado. Memorial Sloan
Kettering Cancer Center (NY).
17 pacientes Julio 2005/junio 2012. La adición
de Beva a la quimioterapia debe producir
respuestas dramáticamente mayores que la
quimio sola.

38. • 5554. Quimioterapia metronómica en cáncer
de ovario en recaída. Fase II. India.
Eto/Cpa/Tamoxifen. 26 pacientes.
Actividad sustancial y duradera. Más estudios.

39. • 5580 Beneficios de la quimioterapia
neoadyuvante en cáncer de ovario.
MD Anderson, Houston, Texas. 163 pacientes.
Es una alternativa a la cirugía. Menos
complicaciones (postoperatorio y otras).
Más estudios.

40. • De las páginas de The ASCO post.
Novel Drug Combination Shows Activity in Recurrent Ovarian
Cancer
Key Points:
• The phase I trial evaluated the effect of combined therapy
against PARP (poli ADP ribosa polimerasa) and angiogenesis
in patients with recurrent ovarian and breast cancer.
• Patients with ovarian cancer achieved a 61% clinical benefit
rate when treated with combination olaparib and cediranib.
None of the evaluable patients with breast cancer achieved
clinical response.
• Grade 3 or higher toxicities occurred in 75% of patients.
• Recomiendan fase II

41. • “The trial began in April 2010, and some
patients have done very well, with a few still
on treatment after over 2 years on trial,” said
lead author Joyce Liu, MD, MPH, a
gynecologic oncologist with the Susan F. Smith
Center for Women’s Cancers at Dana-Farber
Cancer Institute.
Published online in the European Journal of
Cancer.

42. • Pazopanib Maintenance Therapy Extends
Progression-free Survival in Patients with Ovarian
Cancer
• Maintenance therapy with the targeted therapy
pazopanib extended progression-free survival in
women with ovarian cancer who were disease-free
following initial treatment with surgery and
chemotherapy, according to results of a phase III trial
presented by Andreas du Bois, MD, of the Kliniken
Essen Mitte in Essen, Germany, at the 2013 ASCO
Annual Meeting.